UBS raised the firm’s price target on Tenet Healthcare (THC) to $217 from $197 and keeps a Buy rating on the shares. Tenet reported a strong performance across all of its segments for Q3, with outperformance coming in the hospital segment, while the USPI segment in-line with expectations, the analyst tells investors in a research note. The company continues to prioritize investments in the USPI segment as the top capital priority and investments in key hospital growth opportunities also remain a priority, particularly given Tenet’s more streamlined hospital portfolio after a series of divestitures, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on THC:
- Tenet Healthcare price target raised to $183 from $174 at RBC Capital
- Tenet Healthcare Reports Strong Q3 Results and Raises Outlook
- McDonald’s, Ford, Pfizer report Q3 earnings beats: Morning Buzz
- Tenet Healthcare reports Q3 adjusted EPS $2.93 vs. $1.44 last year
- Tenet Healthcare raises FY24 adjusted EPS view to $11.12-$11.73
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
